# Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis

> **NCT03669757** · PHASE1 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 13 (actual)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** LEO 134310
- **DRUG:** LEO 134310
- **DRUG:** LEO 134310
- **DRUG:** LEO 134310
- **DRUG:** LEO 134310 vehicle
- **DRUG:** 0.1% betamethasone valerate ointment (class III steroid)

## Key facts

- **NCT ID:** NCT03669757
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-27
- **Primary completion:** 2019-02-01
- **Final completion:** 2019-02-01
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03669757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03669757, "Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03669757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*